Aberrant glycosylation is a common feature of cancer and includes O-glycan truncation as well as N- and O-linked glycan branching, aberrant sialylation, and fucosylation. CD BioGlyco has developed several efficient Strategies for Sialic Acid Analysis to help our clients’ research. Welcome clients from all over the world to cooperate with us!
Sialylation is an important part of cell function, regulated by the activity and level of sialyltransferase on glycoproteins and glycolipids, and is involved in biological processes such as cell recognition, adhesion, molecular transport, and signal transduction. Excessive sialylation on cancer cells may be due to up-regulation of sialyltransferase, down-regulation of sialidase, or a combination of both, leading to accumulation of sialic acid on the cell surface, which promotes immune evasion, tumor metastasis, and reduced efficacy of chemotherapy and radiotherapy. Abnormal sialylation is associated with a variety of cancers, such as head and neck cancer, cervical cancer, leukemia, lung cancer, breast cancer, ovarian cancer, gastric cancer, melanoma, thyroid cancer, prostate cancer, and hepatocellular carcinoma.
Sialylated proteins and sialyltransferases are used as cancer biomarkers for cancer screening, detection, and staging. For example, prostate-specific antigen (PSA) has been approved for prostate cancer screening, α-fetoprotein for hepatocellular carcinoma diagnosis and monitoring, carbohydrate antigen 125 (CA125) for ovarian cancer detection, and thyroglobulin for the detection of thyroid cancer. ST6GAL1 (ST6 β-galactoside α-2,6-sialyltransferase 1) may have a prognostic role in ovarian cancer and may be used to identify patients with a high risk of chemotherapy resistance and metastatic recurrence. ST3GAL1 (ST3 β-galactoside α-2,3-sialyltransferase 1) is an influencing factor of recurrence and poor prognosis in patients with renal cell carcinoma.
Sialic Acid-Specific Bio-Affinity Strategies have been used to characterize glycosylation changes in body fluids, primary tumor tissues, and cancer cell lines of laryngeal cancer patients.
Sialic Acid-Specific Lectin is used to determine total sialic acid levels, sialidase activity, sialyltransferase, and ligation-specific sialoprotein activity in saliva of patients with oral cancer.
Cholangiocarcinoma is an aggressive malignant tumor originating from bile duct epithelial cells. Serum sialic acid is significantly elevated in cholangiocarcinoma patients.
Studies have shown that changes in sialylation and fucosylation are related to the early onset of cervical cancer. Sialic acid is overexpressed in cervical cancer cells.
In childhood acute lymphoblastic leukemia, increased expression of 9-O-acetylated sialoglycoprotein and 9-O-acetylated disialoganglioside is used as diagnostic and prognostic markers.
Colorectal cancer is one of the most common malignancies in the world. Sialic acid-specific lectin and lectin blotting are used to identify plasma glycoprotein profiles of colorectal cancer biomarkers.
N-Acetylgalactosaminide α-2,6-sialyltransferase 1 is overexpressed in non-small cell lung cancer and serves as a biomarker to differentiate lung adenocarcinoma from lung squamous cell carcinoma.
Increased sialylation is a feature in cancer tissue and blood of breast cancer patients. Therefore, salivary sialic acid may serve as a non-invasive predictive marker in breast cancer patients.
Compared with endometrial hyperplasia patients and normal controls, the total sialic acid content in tissues of endometrial cancer patients is significantly increased.
Stomach cancer is a highly metastatic disease and one of the leading causes of cancer death in the world. CD BioGlyco provides sialic acid analysis services in stomach cancer research for our clients worldwide.
We have been focusing on sialic acid research for many years. Based on our complete Sialic Acid Analysis Service solutions, we provide sialic acid analysis in thyroid cancer for our clients.
The development of melanoma has been found to be associated with increased expression of α2,3-linked sialic acids on the cell surface, residues that promote the interaction of melanoma cells with fibronectin.
Prostate cancer is the second leading cause of cancer death in men. Altered levels of sialylation, fucosylation, Lewis antigen, and sialyl Lewis antigen have been found to be associated with prostate cancer.
Ovarian cancer is the seventh most common cancer in women that develops in or on the ovaries. In ovarian cancer, serum total sialic acid or glycolipid-bound sialic acid is significantly elevated.
CD BioGlyco provides high-quality sialic acid analysis services in cancer by different strategies. If you are interested in our services, please feel free to contact us for more information.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.